Cargando…

Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)

BACKGROUND: Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research. AIMS: This second International Consensus Study of Antipsychotic Dosing provides dosing equivalencies...

Descripción completa

Detalles Bibliográficos
Autores principales:	McAdam, Matthew KT, Baldessarini, Ross J, Murphy, Andrea L, Gardner, David M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612374/ https://www.ncbi.nlm.nih.gov/pubmed/37842908 http://dx.doi.org/10.1177/02698811231205688

Ejemplares similares

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
por: Vázquez, Gustavo H., et al.
Publicado: (2021)

Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
por: Zhao, Ying Jiao, et al.
Publicado: (2016)

Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
por: Pompili, Maurizio, et al.
Publicado: (2016)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
por: Ventriglio, Antonio, et al.
Publicado: (2019)

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
por: Hirsch, Lauren, et al.
Publicado: (2018)

The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study
por: Bodnar, Michael, et al.
Publicado: (2016)

Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
por: Kaikoushi, Katerina, et al.
Publicado: (2021)

Overcoming barriers to monitoring patients taking second-generation antipsychotics
por: Peña, Anita, et al.
Publicado: (2018)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Youth, Caregiver, and Prescriber Experiences of Antipsychotic-Related Weight Gain
por: Murphy, Andrea Lynn, et al.
Publicado: (2013)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
por: Ulcickas Yood, Marianne, et al.
Publicado: (2011)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic, Martha, et al.
Publicado: (2018)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
por: Murphy, Andrea L., et al.
Publicado: (2023)

Arterial Stiffness in Patients Taking Second-generation Antipsychotics
por: Fındıklı, Ebru, et al.
Publicado: (2016)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
por: Caruso, Giuseppe, et al.
Publicado: (2020)

The second ESGAR consensus statement on CT colonography
por: Neri, Emanuele, et al.
Publicado: (2012)

The future of meniscus science: international expert consensus
por: DePhillipo, Nicholas N., et al.
Publicado: (2021)

The Impact of Psychopharmacology on Contemporary Psychiatry
por: Baldessarini, Ross J
Publicado: (2014)

Epidemiology of suicide: recent developments
por: Baldessarini, Ross J.
Publicado: (2019)

Cognitive impairment in adults under compulsory psychiatric care: association with psychotic symptoms and high-dose antipsychotics
por: Karanikola, Maria, et al.
Publicado: (2023)

Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics
por: Oh, Jee-Eun, et al.
Publicado: (2012)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Combination treatment with second generation antipsychotics other than clozapine
por: Schmidt-Kraepelin, C.
Publicado: (2021)

Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics
por: Joo, Sung Woo, et al.
Publicado: (2022)

Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis
por: Ramachandran, Sujith, et al.
Publicado: (2016)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
por: Gurgle, Holly E, et al.
Publicado: (2016)

International multispecialty consensus on how to image, define, and grade ultrasound imaging features of first metatarsophalangeal joint osteoarthritis, a Delphi consensus study
por: Molyneux, Prue, et al.
Publicado: (2023)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Teetering on the Edge: Second-Degree Atrioventricular Block Following Long-Acting Second-Generation Antipsychotic
por: Harrisingh, Kamahl, et al.
Publicado: (2023)

Money matters: does the reimbursement policy for second-generation antipsychotics influence the number of recorded schizophrenia patients and the burden of stigmatization?
por: Kiejna, Andrzej, et al.
Publicado: (2013)

Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
por: Rageth, Christoph J., et al.
Publicado: (2018)

High dose antipsychotic treatment monitoring audit
por: Scott, Jake, et al.
Publicado: (2021)

Tackling constipation in patients on high dose antipsychotics
por: Eappen, Sandhya
Publicado: (2021)

Choosing an Optimal Antipsychotic Dose for Relapse Prevention
por: Davis, John M, et al.
Publicado: (2022)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6al1j0e8ld2si2fsehln2q21pn